The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of regimens targeting the PD-1/PD-L1 axis. In this activity, Roy S. Herbst, MD, PhD and Sarah B. Goldberg, MD, MPH, share the latest data for current and emerging checkpoint inhibitor monotherapies in advanced NSCLC with high PD-L1 expression and provide expert guidance on optimizing frontline treatment selection.
Upon completion of this activity, participants should be better able to:
![Herbst - Suit July 2013[2]](https://www.rmei.com/wp-content/uploads/elementor/thumbs/Herbst-Suit-July-20132-qmsinat6nofmptgsfe8nck7ac6m20qby5jwiso2dlc.jpg "Herbst – Suit July 2013[2]")
Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology
Chief of Medical Oncology
Associate Cancer Center Director, Translational Research
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT
Associate Professor of Medicine (Medical Oncology)
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT
Featured RMEI CE Activities – Earn CE Credit(s)
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
